J Korean Med Sci.  2015 Sep;30(9):1253-1259. 10.3346/jkms.2015.30.9.1253.

AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma

• Kwon JH
• Ahn KS
• Moon YH
• Park JY
• Wang HJ
• Choi KY
• Kim G
• Joh JW
• Lee KG
• Kang KJ

• KMID: 2344149
• DOI: http://doi.org/10.3346/jkms.2015.30.9.1253

Abstract

Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the non-cirrhotic HCC patients (P=0.015) and also in tumor tissues irrespective of tumor stage (P<0.001) or BCLC stage (P<0.001). High mRNA levels of AROS were statistically significantly associated with tumor stage (P<0.001), BCLC stage (P=0.007), alpha fetoprotein (AFP) level (P=0.013), microvascular invasion (P=0.001), tumor size (P=0.036), and portal vein invasion (P=0.005). Kaplan-Meir curve analysis demonstrated that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both the short-term (P<0.001) and long-term (P=0.005) compared to those with low AROS. Cox regression analysis demonstrated that AROS is a significant predictor for DFS along with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, which are the known prognostic factors. In conclusion, AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.

Keyword

Carcinoma, Hepatocellular; Prognosis; Biological Markers

MeSH Terms

Adult
Age Distribution
Aged
Biomarkers, Tumor/*metabolism
Carcinoma, Hepatocellular/*epidemiology/*metabolism/pathology
Disease-Free Survival
Female
Humans
Liver Cirrhosis/epidemiology/metabolism/pathology
Liver Neoplasms/*epidemiology/*metabolism/pathology
Male
Middle Aged
Neoplasm Invasiveness
Nuclear Proteins/*metabolism
Prevalence
Reproducibility of Results
Republic of Korea/epidemiology
Risk Factors
Sensitivity and Specificity
Sex Distribution
Transcription Factors/*metabolism
Young Adult
Biomarkers, Tumor
Nuclear Proteins
Transcription Factors

Figure

• 

  Fig. 1 (A) AROS expression in HCC (T) compared to surrounding non-tumoral tissues (NT) in LC and NonLC. Both cirrhotic and non-cirrhotic tumors expressed significantly higher levels of AROS (P < 0.0001). (B) AROS expression in non-cirrhotic HCC (T) compared to surrounding non-tumoral tissues (NT) in total and across stages. mRNA levels of AROS were significantly up-regulated in tumors compared to non-tumors irrespective of tumor stages and BCLC stages. (C) Comparative analysis of AROS mRNA levels in HCC tissues with (recu) or without postoperative recurrence (non-recu) within 2 yr. AROS expression was higher in recurrent tumors than in non-recurrent tumors exclusively in NonLC, but not LC.

• 

  Fig. 2 Non-cirrhotic HCC patients with high levels of AROS expression have a shorter DFS for 2 yr. Kaplan-Meier curves for the DFS of patients who showed high expression and low expression of AROS. (A) AUC value of AROS expression at prediction of DFS was 0.576. (B) The AROS-high group showed a significantly shorter DFS time than the AROS-low group for 2 yr (P < 0.001). Thin lines, patients expressed higher levels of AROS (n = 71); broken lines, patients expressed lower levels of AROS (n = 212).

Reference

1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7:448–458.

2. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984; 4:136–146.

3. Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A, Grazi GL, Gozzetti G, Gasbarrini G, Bernardi M. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer. 1995; 75:2220–2232.

4. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996; 105:65–75.

5. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19:271–285.

6. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115:209–218.

7. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010; 42:341–347.

8. Xu L, Huang L, Li BK, Zhang YQ, Li JQ, Yuan YF. Clinicopathologic features and long-term outcomes of Chinese patients with hepatocellular carcinoma in non-cirrhotic liver. Dig Surg. 2008; 25:376–382.

9. Laurent C, Blanc JF, Nobili S, Sa Cunha A, le Bail B, Bioulac-Sage P, Balabaud C, Capdepont M, Saric J. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg. 2005; 201:656–662.

10. Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg. 1995; 19:35–41.

11. Nagasue N, Ono T, Yamanoi A, Kohno H, El-Assal ON, Taniura H, Uchida M. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001; 88:515–522.

12. Chen MF, Tsai HP, Jeng LB, Lee WC, Yeh CN, Yu MC, Hung CM. Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg. 2003; 27:443–447.

13. Kim EJ, Um SJ. SIRT1: roles in aging and cancer. BMB Rep. 2008; 41:751–756.

14. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci. 2012; 1271:10–19.

15. Maeda N, Toku S, Kenmochi N, Tanaka T. A novel nucleolar protein interacts with ribosomal protein S19. Biochem Biophys Res Commun. 2006; 339:41–46.

16. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell. 2007; 28:277–290.

17. Knight JR, Allison SJ, Milner J. Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity. Open Biol. 2013; 3:130130.

18. Knight JR, Willis AE, Milner J. Active regulator of SIRT1 is required for ribosome biogenesis and function. Nucleic Acids Res. 2013; 41:4185–4197.

19. Kwon JH, Kim J, Park JY, Hong SM, Park CW, Hong SJ, Park SY, Choi YJ, Do IG, Joh JW, et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res. 2010; 16:5511–5521.

20. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3:RESEARCH0034.

21. Smalley SR, Moertel CG, Hilton JF, Weiland LH, Weiand HS, Adson MA, Melton LJ 3rd, Batts K. Hepatoma in the noncirrhotic liver. Cancer. 1988; 62:1414–1424.

22. Capussotti L, Muratore A, Amisano M, Massucco P, Polastri R, Bouzari H. Liver resection for large-size hepatocellular carcinomas in 47 non-cirrhotic patients--no mortality and long-term survival. Hepatogastroenterology. 2006; 53:768–772.

23. Donati G, Montanaro L, Derenzini M. Ribosome biogenesis and control of cell proliferation: p53 is not alone. Cancer Res. 2012; 72:1602–1607.

24. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010; 29:4253–4260.

25. Belin S, Beghin A, Solano-Gonzalez E, Bezin L, Brunet-Manquat S, Textoris J, Prats AC, Mertani HC, Dumontet C, Diaz JJ. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One. 2009; 4:e7147.

26. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol. 2012; 19:2011–2019.

27. Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012; 7:e45119.

28. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6:674–687.

29. Beard RE, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery. 2013; 154:545–555.